Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TransCon RBZ
- Development stage
- Preclinical
- Lead developer
- Ascendis Pharma
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Ophthalmic
01
Overview
TransCon RBZ is an investigational, sustained-release formulation of ranibizumab designed using Ascendis Pharma’s TransCon prodrug technology to enable extended intraocular delivery for retinal diseases such as neovascular (wet) age-related macular degeneration. It is part of Ascendis’ newly created ophthalmology effort and was disclosed as the first pipeline candidate in that franchise. Mechanistically, ranibizumab is a monoclonal antibody fragment that binds vascular endothelial growth factor A (VEGF-A), inhibiting VEGF-A signaling to reduce pathologic ocular neovascularization and vascular permeability. Public reports place TransCon RBZ in preclinical development for wet AMD under Ascendis Pharma’s ophthalmology unit.
- Other names
- ranibizumab TransCon
02
Targets
Beyond the preview
Go deeper on TransCon RBZ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TransCon RBZ.